What amount sold does American Gene Technologies International Inc. report in Form D filings?

The latest linked filings report $2.8M sold across 4 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was American Gene Technologies International Inc.'s most recent SEC filing?

American Gene Technologies International Inc.'s most recent Form D filing was on 2025-12-22.

How many investors does American Gene Technologies International Inc. have?

The most recent Form D filing lists 4 investor(s).

American Gene Technologies International Inc.

CIK: 0001586824·Biotechnology·ROCKVILLE, MD

Reported Sold

$2,828,998

Total Filings

Identified Offerings

Last Filed

Dec 22, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

Offering filing timeline

Dec 22, 2025Form D/A — Amendment

Reported sold: $310,000 · Target: $10,000,000

No verified predecessor available.

Rule 506(b)·4 investors

Nov 18, 2025Form D — New notice

Reported sold: $0 · Target: $10,000,000

Rule 506(b)·0 investors

Nov 12, 2015Form D — New notice

Reported sold: $1,163,007 · Target: $4,350,000

Rule 506(b)·14 investors

Oct 3, 2014Form D — New notice

Reported sold: $340,992 · Target: $1,999,999

Rule 506(b)·1 investor

Sep 16, 2013Form D — New notice

Reported sold: $1,324,999 · Target: $1,324,999

Rule 506·2 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

20%

Latest reported sold across 4 identified offerings

$2,828,998

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

Jeffrey Galvin

Related Person

Appears on 3 filings

Jeffrey Adam Galvin

Executive Officer, Director

Appears on 2 filings

William Drew Palin

Executive Officer, Director

Appears on 2 filings

Barry Haden Wells

Director

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Dec 22, 2025	Amendment	$10,000,000	$310,000	4
Nov 18, 2025	New	$10,000,000	$0	0
Nov 12, 2015	New	$4,350,000	$1,163,007	14
Oct 3, 2014	New	$1,999,999	$340,992	1
Sep 16, 2013	New	$1,324,999	$1,324,999	2

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

OS Therapies Inc

Biotechnology

Offering target: $12,282,478

Filed Oct 23, 2026